Leukemia research最新文献

筛选
英文 中文
Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era. 新分类时代成人T细胞白血病/淋巴瘤病理学认识的最新进展。
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-12-06 DOI: 10.1016/j.leukres.2024.107634
Kennosuke Karube, Shugo Sakihama, Mitsuyoshi Takatori, Kazuho Morichika, Tomoko Tamaki, Naoki Wada, Takuya Fukushima
{"title":"Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.","authors":"Kennosuke Karube, Shugo Sakihama, Mitsuyoshi Takatori, Kazuho Morichika, Tomoko Tamaki, Naoki Wada, Takuya Fukushima","doi":"10.1016/j.leukres.2024.107634","DOIUrl":"https://doi.org/10.1016/j.leukres.2024.107634","url":null,"abstract":"<p><p>Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by Human T-cell leukemia virus type 1 (HTLV-1) infection. Although the 5th Edition of the WHO classification (WHO-5) did not make drastic changes regarding the disease concept of ATLL from the revised 4th Edition of the WHO classification (WHO-4R), WHO-5 newly introduced the essential and desirable diagnostic criteria, namely, \"neoplastic lymphoid cell proliferation with mature T-cell phenotype; proven HTLV-1 carriership\" and \"identification of monoclonal integration of HTLV-1\", respectively. To satisfy the desirable criteria, a new diagnostic method using a combination of HBZ-ISH and tax-PCR was introduced for the identification of the HTLV-1 in addition to the conventionally used Southern blot hybridization, especially in the case when only FFPE specimens are available. Morphologically, pleomorphic- and anaplastic large cell-type, account for most cases, while minor variants, ATLL with dermatopathic reaction, angioimmunoblastic T-cell lymphoma-like variant, and classic Hodgkin lymphoma-like variant, should also be noted as diagnostic pitfalls. Phenotypically, about 80 % of ATLL cases show a typical phenotype of CD3 + CD4 +CD25 +CCR4 + , while about 10 % show atypical phenotypes such as T follicular helper cell-like one. Many genetic abnormalities, mainly associated with the TCR signaling pathway, are observed, and most are more frequent in the aggressive type than in the indolent type, except for STAT3, indicating the heterogeneous pathogenic process of ATLL. In this review, we present the latest findings on molecular pathogenesis and histopathological findings of ATLL in the era of the new classification of lymphomas, serving as a basis for future research and classification.</p>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"107634"},"PeriodicalIF":2.1,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-12-05 DOI: 10.1016/j.leukres.2024.107635
Devon A Weterings, Aileen G Rowan, Lucy B Cook
{"title":"Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).","authors":"Devon A Weterings, Aileen G Rowan, Lucy B Cook","doi":"10.1016/j.leukres.2024.107635","DOIUrl":"https://doi.org/10.1016/j.leukres.2024.107635","url":null,"abstract":"<p><p>Human T-cell leukaemia virus type-1 (HTLV-1) causes the highly aggressive malignancy adult T-cell leukaemia-lymphoma (ATL) in approximately 5 % of chronically infected carriers. HTLV-1 persists in the host by enhancing survival of infected-T-cells despite the presence of a strong immune response. Therefore, asymptomatic HTLV-1 carriers have a lifelong balance between infected cell proliferation and the host antiviral immune response. However, this immunological balance is lost in patients with ATL. Reliable treatment options are lacking and there is urgent need for new treatment strategies to improve the dismal prognosis of ATL. In this review, we present a summary of the current knowledge on the immunological aspects of HTLV-1 persistence and the immune alterations observed in ATL, and discuss how the recent emerging advances in adoptive immunotherapy may offer a prevention and treatment option for ATL.</p>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"107635"},"PeriodicalIF":2.1,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques 利用机器学习技术为接受异基因造血干细胞移植的急性白血病患者建立预后模型
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-20 DOI: 10.1016/j.leukres.2024.107619
Maedeh Rouzbahani , Seyed Amirhossein Mousavi , Ghasem Hajianfar , Ali Ghanaati , Mohammad Vaezi , Ardeshir Ghavamzadeh , Maryam Barkhordar
{"title":"Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques","authors":"Maedeh Rouzbahani ,&nbsp;Seyed Amirhossein Mousavi ,&nbsp;Ghasem Hajianfar ,&nbsp;Ali Ghanaati ,&nbsp;Mohammad Vaezi ,&nbsp;Ardeshir Ghavamzadeh ,&nbsp;Maryam Barkhordar","doi":"10.1016/j.leukres.2024.107619","DOIUrl":"10.1016/j.leukres.2024.107619","url":null,"abstract":"<div><h3>Background</h3><div>Leukemia necessitates continuous research for effective therapeutic techniques. Acute leukemia (AL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) focus on key outcomes such as overall survival (OS), relapse, and graft-versus-host disease (GVHD).</div></div><div><h3>Objective</h3><div>This study aims to evaluate the capability of machine learning (ML) models in predicting OS, relapse, and GVHD in AL patients post-allo-HSCT.</div></div><div><h3>Methods</h3><div>Clinical data from 1243 AL patients, with 10 years of follow-up, was utilized to develop 28 ML models. These models incorporated four feature selection methods and seven ML algorithms. Model performance was assessed using the concordance index (c-index) with multivariate analysis.</div></div><div><h3>Results</h3><div>The multivariate model analysis showed the best FS/ML combinations were UCI_GLMN, IBMA_GLMN and IBMA_CB for OS, UCI_ST, UCI_RSF, UCI GLMB, UCI_GB, UCI_CB, MI_GLMN, IBMA_ST and IBMA GB for relapse, IBMA_GB for aGVHD and Boruta_GB for cGVHD (all p values &lt; 0.0001, mean C-indices in 0.61–0.68)).</div></div><div><h3>Conclusion</h3><div>ML techniques, when combined with clinical variables, demonstrate high accuracy in predicting OS, relapse, and GVHD in AL patients.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107619"},"PeriodicalIF":2.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study Luspatercept 对骨髓增生异常综合征患者输注红细胞的实际影响:美国医疗索赔数据库研究
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-17 DOI: 10.1016/j.leukres.2024.107624
Leslie A. Andritsos , Ali McBride , Derek Tang , Victoria Barghout , Enrico Zanardo , Rui Song , Lynn Huynh , Mihran Yenikomshian , Adeola Y. Makinde , Christina Hughes , Kirollos S. Hanna , Kashyap Patel
{"title":"Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study","authors":"Leslie A. Andritsos ,&nbsp;Ali McBride ,&nbsp;Derek Tang ,&nbsp;Victoria Barghout ,&nbsp;Enrico Zanardo ,&nbsp;Rui Song ,&nbsp;Lynn Huynh ,&nbsp;Mihran Yenikomshian ,&nbsp;Adeola Y. Makinde ,&nbsp;Christina Hughes ,&nbsp;Kirollos S. Hanna ,&nbsp;Kashyap Patel","doi":"10.1016/j.leukres.2024.107624","DOIUrl":"10.1016/j.leukres.2024.107624","url":null,"abstract":"<div><div>Myelodysplastic syndromes (MDS) are associated with anemia and the need for blood transfusions. In clinical trials, luspatercept reduced transfusion dependency among patients with lower-risk MDS. This United States (US) study describes real-world clinical outcomes pre- and post-luspatercept initiation among patients with MDS. Symphony Health Integrated Dataverse claims data (August 1, 2010−December 29, 2022) were used to identify patients with MDS treated with luspatercept (first luspatercept claim = index date). Transfusion-dependent (TD) or non-TD (NTD) patients at baseline were described as 8-week transfusion-independent (TI) or as maintaining NTD, respectively, if they had no transfusion for 8 weeks in the 6 months post-index (similarly for 12, 16, and 24 weeks). Transfusion status was measured overall and among patients who were baseline NTD, TD, TD and exposed to erythropoiesis-stimulating agents (ESA) (TD+ESA-exposed), MDS with ring sideroblasts (RS) (MDS-RS), and MDS-non-RS. MDS-related treatments were measured pre- and post-index. Among the 871 patients who received luspatercept (mean age: 74.7 years), 87.4 % achieved 8-week TI/maintained NTD within 6 months post-index, 64.9 % of patients did not receive additional MDS-related treatments post-luspatercept initiation (median follow-up: 14.8 months), 98.5 % of baseline NTD patients maintained 8-week NTD 6 months post-luspatercept initiation, and 88.6 % did not receive a transfusion for 24 weeks. Baseline TD (64.2 %) and TD+ESA-exposed (64.2 %) patients achieved 8-week TI 6 months post-luspatercept initiation. Eight-week TI proportions were similar between MDS-RS (89.8 %) and MDS-non-RS (84.8 %) subgroups. These findings corroborate clinical trial data by showing the high effectiveness of luspatercept among real-world patients with MDS in the US.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107624"},"PeriodicalIF":2.1,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the impact of methylation aging on acute myeloid leukemia: Insights from the aging clock 探索甲基化老化对急性髓性白血病的影响:老化时钟的启示
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-15 DOI: 10.1016/j.leukres.2024.107620
Jin-Young Kim , Karthikeyan A. Vijayakumar , Gwang-Won Cho
{"title":"Exploring the impact of methylation aging on acute myeloid leukemia: Insights from the aging clock","authors":"Jin-Young Kim ,&nbsp;Karthikeyan A. Vijayakumar ,&nbsp;Gwang-Won Cho","doi":"10.1016/j.leukres.2024.107620","DOIUrl":"10.1016/j.leukres.2024.107620","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is more commonly diagnosed in adults. Though there are considerable knowledge about the relationship between adult leukemia and aging, it is rarely studies in children as the occurrence of the disease is rare. Additionally, adult and pediatric AML are known to have different etiology. Studies show that in adult AML, methylation aging is accelerated compared to healthy people. However, this association has not been extensively studied in pediatric AML. To investigate potential correlations between pediatric AML and aging, we analyzed methylation aging clock models that leverage DNA methylation patterns and predict epigenetic age. By established knowledge, we observed that the predicted epigenetic age in adult AML cases exceeds the actual chronological age. Similarly, we found that predicted epigenetic age in pediatric AML cases was also higher than chronological age. In addition, we observed significant changes in the CpG probes of the Epi clock, and these changes were observed to be extensive hypomethylation. Based on this, we found that the Epi clock can recognize changes specific to AML. These findings may have implications for strategies to address aging and quality of life after treatment in pediatric AML patients.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107620"},"PeriodicalIF":2.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia NAP1L5 通过调节急性髓性白血病中 PEG10 的表达促进上皮-间质转化。
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-13 DOI: 10.1016/j.leukres.2024.107623
Huan Wu , Hang Luo , Meng Wang , YuQing Du , Jiajia Li
{"title":"NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia","authors":"Huan Wu ,&nbsp;Hang Luo ,&nbsp;Meng Wang ,&nbsp;YuQing Du ,&nbsp;Jiajia Li","doi":"10.1016/j.leukres.2024.107623","DOIUrl":"10.1016/j.leukres.2024.107623","url":null,"abstract":"<div><div>Acute myeloid leukaemia (AML) is a haematological malignancy that poses a serious threat to human health. Studies have shown that the expression of NAP1L5 is elevated in patients with AML; however, the specific molecular mechanism remains unknown. Therefore, in this study, we aimed to investigate the pathogenic mechanisms of NAP1L5 in AML. The expression level of NAP1L5 was increased in AML, and the upregulation of NAP1L5 was related to tumour growth and epithelial–mesenchymal transition. Furthermore, PEG10 is a downstream regulatory factor of NAP1L5, and its overexpression promotes tumour growth and epithelial–mesenchymal transition. More importantly, the loss of PEG10 inhibited the negative effects induced by NAP1L5 overexpression. Our results suggest that NAP1L5 is a novel therapeutic target for AML treatment.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107623"},"PeriodicalIF":2.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide 与RCHOP加来那度胺不同,RCHOP加BTK抑制剂可改善双表达弥漫大B细胞淋巴瘤的临床疗效。
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-09 DOI: 10.1016/j.leukres.2024.107622
Demei Feng, Shenrui Bai, Dong Liang, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Hua Wang
{"title":"RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide","authors":"Demei Feng,&nbsp;Shenrui Bai,&nbsp;Dong Liang,&nbsp;Xiaoqin Chen,&nbsp;Zhongjun Xia,&nbsp;Yang Liang,&nbsp;Hua Wang","doi":"10.1016/j.leukres.2024.107622","DOIUrl":"10.1016/j.leukres.2024.107622","url":null,"abstract":"<div><h3>Background</h3><div>Double-expressor diffuse large B-cell lymphoma (DE-DLBCL) has a poor prognosis, and optimal treatment strategies remain unclear. This study evaluates the efficacy and safety of RCHOP, R2-CHOP (RCHOP plus lenalidomide), and RCHOP plus Bruton's Tyrosine Kinase inhibitors (BTKi) in DE-DLBCL treatment.</div></div><div><h3>Methods</h3><div>Data from 213 DE-DLBCL patients treated from January 2019 and February 2024. Among them, 112 received R-CHOP, 65 received R2-CHOP, and 36 received R-CHOP plus BTKi. We evaluated clinical characteristics, overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) for each groups.</div></div><div><h3>Results</h3><div>Baseline characteristics were comparable across groups. ORRs were 95.5 % for R-CHOP, 96.9 % for R2-CHOP, and 97.2 % for R-CHOP plus BTKi, with CR rates of 76.5 %, 80 %, and 75 %, respectively. BTKi significantly improved PFS (p=0.033) but not affect OS (p=0.165). Lenalidomide showed no benefit in PFS (p=0.153) or OS (p=0.351). With median follow-up times of 20.6 months for R-CHOP, 23.5 months for R2-CHOP, and 17.6 months for R-CHOP plus BTKi, the 1-year PFS rates were 73.6 %, 82.2 %, and 93.3 %, and the 1-year OS rates were 96.2 %, 93.2 %, and 100 %, respectively. Grade 3–4 adverse events included leukopenia, neutropenia, and anemia, and thrombocytopenia, with no significant differences among groups.</div></div><div><h3>Conclusion</h3><div>The addition of BTK inhibitor enhances progression-free survival in DE-DLBCL, especially in advanced-stage patients, without introducing new severe adverse reactions. In contract, adding lenalidomide does not offer additional efficacy or survival benefits.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107622"},"PeriodicalIF":2.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study 基因预测的 731 种免疫细胞表型在慢性淋巴白血病中的因果作用:一项双向孟德尔随机化研究。
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-09 DOI: 10.1016/j.leukres.2024.107621
Suying Qian, Jiali Gong, Xiu Shen, Mengjie Chen, Yiquan Cheng, Jingwen Zhu, Mengmeng Huang, Zhilong Shi, Gangfeng Xiao, Keyue Hu, Kesang Li
{"title":"Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study","authors":"Suying Qian,&nbsp;Jiali Gong,&nbsp;Xiu Shen,&nbsp;Mengjie Chen,&nbsp;Yiquan Cheng,&nbsp;Jingwen Zhu,&nbsp;Mengmeng Huang,&nbsp;Zhilong Shi,&nbsp;Gangfeng Xiao,&nbsp;Keyue Hu,&nbsp;Kesang Li","doi":"10.1016/j.leukres.2024.107621","DOIUrl":"10.1016/j.leukres.2024.107621","url":null,"abstract":"<div><h3>Introduction</h3><div>The direct causal relationship between these anomalies and chronic lymphatic leukemia (CLL) remains ambiguous. This study sought to investigate the potential causal link between immune cells and CLL.</div></div><div><h3>Materials and methods</h3><div>The summary data for genome-wide association studies utilized in this research were sourced from various publicly accessible databases, including the GWAS and FinnGen databases. By amalgamating these extensive genetic resources, we applied an array of cutting-edge Mendelian randomization (MR) analytical techniques. Specifically, we employed the inverse variance weighting (IVW) method, the weighted median method, the MR-Egger method, the Cochran Q test, Leave-One-Out sensitivity analysis, and the weighted model method to rigorously evaluate the potential causal link between multiple immune cell phenotypes and CLL.</div></div><div><h3>Results</h3><div>IVW analyses consistently demonstrated significant causal associations between five groups of immune cells and CLL. These associations were observed in both forward MR analyses from immune cells to CLL, and reverse MR analyses from CLL to immune cells. The five groups of immune cells under investigation included CD14+ CD16- monocyte Absolute Count, CD4+CD8+ T cell Absolute Count, BAFF-R on IgD- CD27- B cell, HLA DR+ T cell Absolute Count, and CD4+ T cell Absolute Count. Further sensitivity analyses not only confirmed the consistency in the direction of the association but also ruled out potential heterogeneity and horizontal pleiotropy effects. This enhanced the robustness and reliability of the study findings.</div></div><div><h3>Conclusion</h3><div>This investigation discerned definitive causal links between five immune cell phenotypes and CLL, underscoring the pivotal role of immune cells in the pathogenesis of this disease.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107621"},"PeriodicalIF":2.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience 同种异体干细胞移植成人和儿童受者中的 COVID-19 感染:英国的经验。
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-08 DOI: 10.1016/j.leukres.2024.107618
Giovanna Lucchini, Elena Cozma, Aimee Jackson, Kimberly Gilmour, Rachel Protheroe, Keith Wilson, Karl Peggs, Victoria Potter, Anne Parker, Andy Peniket, Eleni Tholouli, Robert Wynn, Emma Nicholson, Charles Craddock, David I. Marks, Christopher Parrish, Shankara Paneesha, Oana Mirci-Danicar, Alexander M. Martin, Graham McIlroy, Persis J. Amrolia
{"title":"COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience","authors":"Giovanna Lucchini,&nbsp;Elena Cozma,&nbsp;Aimee Jackson,&nbsp;Kimberly Gilmour,&nbsp;Rachel Protheroe,&nbsp;Keith Wilson,&nbsp;Karl Peggs,&nbsp;Victoria Potter,&nbsp;Anne Parker,&nbsp;Andy Peniket,&nbsp;Eleni Tholouli,&nbsp;Robert Wynn,&nbsp;Emma Nicholson,&nbsp;Charles Craddock,&nbsp;David I. Marks,&nbsp;Christopher Parrish,&nbsp;Shankara Paneesha,&nbsp;Oana Mirci-Danicar,&nbsp;Alexander M. Martin,&nbsp;Graham McIlroy,&nbsp;Persis J. Amrolia","doi":"10.1016/j.leukres.2024.107618","DOIUrl":"10.1016/j.leukres.2024.107618","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107618"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report 一名 70 岁寡单核细胞慢性粒单核细胞白血病患者的诊断难题和标准应用:病例报告。
IF 2.1 4区 医学
Leukemia research Pub Date : 2024-11-08 DOI: 10.1016/j.leukres.2024.107616
Xiaomei Wang, Tao Chen
{"title":"Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report","authors":"Xiaomei Wang,&nbsp;Tao Chen","doi":"10.1016/j.leukres.2024.107616","DOIUrl":"10.1016/j.leukres.2024.107616","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107616"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信